Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin

International Journal of Cancer

Volumn 129, Issue 8, 2011, Pages 1806-1814

  Lu, Wen Jing ^a   Lee, Nikki P ^a   Kaul, Sunil C ^b   Lan, Feng ^c   Poon, Ronnie T P ^a   Wadhwa, Renu ^b   Luk, John M ^a,d,e  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

human hepatocellular carcinoma; mortalin; mutant p53 dependent apoptosis; RNAi; therapy

Indexed keywords

HEAT SHOCK PROTEIN; MORTALIN; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL IMMORTALIZATION; CONTROLLED STUDY; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; MUTANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENES, P53; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MUTATION; RNA, SMALL INTERFERING;

EID: 80052036411     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25857     Document Type: Article

References (36)

1. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC,. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201-16. (Pubitemid 36292963)
2. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C,. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-29. (Pubitemid 36842561)
3. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M,. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9. (Pubitemid 46744292)
4. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C,. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005; 65: 2108-14. (Pubitemid 40490116)
5. Speidel D, Helmbold H, Deppert W,. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene 2006; 25: 940-53. (Pubitemid 43237712)
6. Nikolaev AY, Li M, Puskas N, Qin J, Gu W,. Parc: a cytoplasmic anchor for p53. Cell 2003; 112: 29-40. (Pubitemid 36106416)
7. Zhao LY, Liao DQ,. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol 2003; 77: 13171-81. (Pubitemid 37494313)
8. Wadhwa R, Taira K, Kaul SC,. Mortalin: a potential candidate for biotechnology and biomedicine. Histol Histopathol 2002; 17: 1173-7.
9. Kaul SC, Deocaris CC, Wadhwa R,. Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol 2007; 42: 263-74. (Pubitemid 46356847)
10. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, Kaul SC,. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006; 118: 2973-80.
11. Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST,. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 2008; 7: 315-25. (Pubitemid 351298446)
12. Dundas SR, Lawrie LC, Rooney PH, Murray GI,. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005; 205: 74-81. (Pubitemid 40029095)
13. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE, Hanash SM,. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003; 278: 7607-16. (Pubitemid 36800769)
14. Deocaris CC, Kaul SC, Wadhwa R,. Heat shock chaperone mortalin and carcinogenesis. In:, Calderwood KS, Sherman MY, Ciocca DR, eds. Heat shock proteins in cancer. Netherlands: Springer, 2007. 141-158.
15. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC,. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998; 273: 29586-91. (Pubitemid 28509966)
16. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R,. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 2005; 280: 39373-9. (Pubitemid 41713894)
17. Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn NG, Fukasawa K,. Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene 2006; 25: 5377-90. (Pubitemid 44330281)
18. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H, Kaul SC,. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 2000; 60: 6818-21. (Pubitemid 32059144)
19. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, Fan ST,. Identification of liver-intestine cadherin in hepatocellular carcinoma-a potential disease marker. Biochem Biophys Res Commun 2003; 311: 618-24. (Pubitemid 37377699)
20. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC, Poon RT,. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 2009; 9: 389.
21. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. HEPATOLOGY 2009; 50: 1453-63.
22. Lee NP, Leung KW, Wo JY, Tam PC, Yeung WS, Luk JM,. Blockage of testicular connexins induced apoptosis in rat seminiferous epithelium. Apoptosis 2006; 11: 1215-29. (Pubitemid 44035969)
23. Laptenko O, Prives C,. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006; 13: 951-61.
24. Vousden KH, Lane DP,. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-83. (Pubitemid 46474662)
25. Gudkov AV, Komarova EA,. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3: 117-29. (Pubitemid 37328879)
26. Leu JI, George DL,. Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev 2007; 21: 3095-109. (Pubitemid 350223527)
27. Rubin P, Casarett GW,. Clinical radiation pathology as applied to curative radiotherapy. Cancer 1968; 22: 767-78.
28. Luk JM, Lam CT, Siu AFM, Lam BY, Ng IOL, Hu MY, Che CM, Fan ST,. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 2006; 6: 1049-57. (Pubitemid 43260229)
29. Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, Poon RT, Peng J, Leng X, Beretta L, Sun S, Day PJ, Luk JM,. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res 2009; 8: 1293-303.
30. Ishioka C, Englert C, Winge P, Yan YX, Engelstein M, Friend SH,. Mutational analysis of the carboxy-terminal portion of p53 ssing both yeast and mammalian-cell assays in-vivo. Oncogene 1995; 10: 1485-92.
31. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M,. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995; 9: 2170-83.
32. Caelles C, Helmberg A, Karin M,. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-23. (Pubitemid 24236778)
33. Nelson V, Davis GE, Maxwell SA,. A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 2001; 6: 221-34. (Pubitemid 32423731)
34. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR,. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-4. (Pubitemid 38209704)
35. Raffo AJ, Kim AL, Fine RL,. Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 2000; 19: 6216-228. (Pubitemid 32641835)
36. Geng Y, Walls KC, Ghosh AP, Akhtar RS, Klocke BJ, Roth KA,. Cytoplasmic p53 and activated Bax regulate p53-dependent, transcription-independent neural precursor cell apoptosis. J Histochem Cytochem 2010; 58: 265-75.